2026-04-13T02:15:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4661452026-03-28T08:21:29Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Fionda, Laura author Lauletta, Antonio author Leonardi, Luca author Alonso Pérez, Jorge author Morino, Stefania author Merlonghi, Gioia author Alfieri, Girolamo author Costanzo, Rocco author Tufano, Laura author Vanoli, Fiammetta author Rossini, Elena author Vigo, Eduard Gallardo author Tartaglione, Tommaso author Salvetti, Marco author Antonini, Giovanni author Diaz-Manera, Jordi author Garibaldi, Matteo author Universitat Autònoma de Barcelona author 2022 Immune-mediated necrotizing myopathy (IMNM) is the most severe idiopathic inflammatory myopathy (IIM) and early aggressive poly-immunotherapy is often required to reduce long-term disability. The aim of this study is to investigate muscle MRI in IMNM as outcome measure for disease activity, severity, progression, response to treatment, and to better characterize the pattern of muscle involvement. This is a retrospective, observational, cross-sectional, and longitudinal study including 22 IMNM patients, divided into three groups based on timing of first MRI and if performed before or under treatment. T1 score and percentage of STIR positive muscles (STIR%) were considered and analyzed also in relation to demographic, clinical and laboratory characteristics. STIR% was higher in untreated patients and in those who performed MRI earlier (p = 0.001). Pelvic girdle and thighs were in general more affected than legs. T1 score was higher in patients with MRI performed later in disease course (p = 0.004) with a prevalent involvement of the lumbar paraspinal muscles, gluteus medius and minimus, adductor magnus and hamstrings. 22% of STIR positive muscles showed fat replacement progression at second MRI. Higher STIR% at baseline correlated with higher risk of fat replacement at follow-up (p = 0.003); higher T1 score correlated with clinical disability at follow-up, with late treatment start and delayed treatment with IVIG (p = 0.03). Muscle MRI is a sensitive biomarker for monitoring disease activity and therapy response, especially when performed early in disease course and before treatment start, and could represent a supportive outcome measure and early prognostic index in IMNM. Immune mediated necrotizing myopathy (IMNM) Whole body muscle MRI Inflammatory myopathies Immunomodulating therapy Follow-up study Muscle MRI in immune-mediated necrotizing myopathy (IMNM) : implications for clinical management and treatment strategies